

WARF Launches Essay Series Highlighting University Innovation

MADISON, WI, UNITED STATES, May 21, 2025 /EINPresswire.com/ -- The Wisconsin Alumni Research Foundation is proud to introduce "[How Wisconsin Ingenuity Benefits the World](#)," a new essay series commemorating its 100th anniversary. This series aims to highlight the significant impact of university innovation on global well-being.

The inaugural essay, authored by Kevin Conroy, Chairman and CEO of Exact Sciences, is titled "[How Wisconsin Ingenuity Is Shaping the Future](#)." Conroy's essay explores the pivotal role that Wisconsin's innovative spirit plays in driving scientific discovery and economic growth. He shares his personal experiences with WARF, emphasizing its support in transforming groundbreaking research into real-world applications.

Conroy highlights how WARF's strategic investments and collaborative efforts have been instrumental in turning lesser-known scientific discoveries into transformative technologies. For example, a variation of an enzyme discovered by Jim Dahlberg became part of the cervical cancer test developed at Third Wave Technologies and is now used in Exact Sciences' Cologuard® test, which has screened over 19 million people for colorectal cancer.

Throughout the year, WARF will publish additional essays from various thought leaders, each offering unique perspectives on the impact of university research on global challenges. These essays will be available at warf.org/WisconsinIngenuity and will underscore the importance of long-term investments in university innovation and the transformative potential of academic-industry partnerships.

About WARF

Celebrating a century of service in 2025, the Wisconsin Alumni Research Foundation (WARF) patents and licenses discoveries from UW-Madison research, manages an investment portfolio



WARF's new essay series highlights how Wisconsin ingenuity is transforming the world.

generated from licensing and investment proceeds, and provides annual grants to the University of Wisconsin-Madison and the Morgridge Institute for Research to support further scientific investigation and research. By driving collaborations among researchers, investors, industry and entrepreneurs, WARF commercializes innovations from campus through various initiatives. WARF Accelerator improves the commercialization potential of university intellectual property through industry engagement and investment in proof-of-concept milestones to validate market potential, demonstrate commercial value and de-risk technology. WARF Therapeutics partners with UW-Madison and Morgridge Institute researchers employing an industry-focused approach to improve the value propositions of drug candidates. WARF Ventures is an early-stage venture fund that invests in startups based on UW/WARF technologies. Learn more at warf.org.

Jeanan Yasiri Moe

Wisconsin Alumni Research Foundation (WARF)

+1 608-960-9892

jyasirimoe@warf.org

Visit us on social media:

[LinkedIn](#)

[Bluesky](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/813993476>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.